Clincosm LogoSign in Get a demo

triple negative breast cancer (tnbc)

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)

Not yet recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Combination of liposomal doxorubicin
  • Elizabeth, New Jersey
  • +7 more
Jul 13, 2023

Advanced Cancer, Advanced Malignancies, Bladder Cancer Trial (AB598, Zimberelimab, Carboplatin)

Not yet recruiting
  • Advanced Cancer
  • +11 more
  • (no location specified)
May 26, 2023

Triple Negative Breast Cancer (TNBC) Trial in China (B013+Nab-Paclitaxel)

Recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Guangzhou, Guangdong, China
  • +6 more
Jan 29, 2023

NSCLC (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC) Trial in Worldwide (NZV930, PDR001,

Terminated
  • Non-small Cell Lung Cancer (NSCLC)
  • +6 more
  • NZV930
  • +2 more
  • Tampa, Florida
  • +9 more
Nov 2, 2022

Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma Trial in Boston (Onvansertib, Paclitaxel)

Recruiting
  • Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +2 more
Oct 25, 2022

Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer Trial in United Kingdom (NX-1607)

Recruiting
  • Ovarian Cancer, Epithelial
  • +14 more
  • Sutton, Surrey, United Kingdom
  • +6 more
Jul 22, 2022

Triple Negative Breast Cancer (TNBC) Trial (Pembrolizumab, Nab-paclitaxel, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer (TNBC)
  • Pembrolizumab
  • +5 more
  • (no location specified)
Jul 15, 2022

Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound,

No longer available
  • Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
  • +3 more
  • (no location specified)
May 20, 2022

Triple Negative Breast Cancer (TNBC) Trial in El Segundo (Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl)

Withdrawn
  • Triple Negative Breast Cancer (TNBC)
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Mar 28, 2022

Triple Negative Breast Cancer (TNBC) Trial in Changchun (Camrelizumab, Doxorubicin, Cyclophosphamide)

Recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Changchun, Jilin, China
    Aiping Shi
Oct 11, 2021

NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), NSCLC (NSCLC) Trial (Birabresib)

Terminated
Has Results
  • NUT Midline Carcinoma (NMC)
  • +3 more
  • (no location specified)
Jan 7, 2021

Triple Negative Breast Cancer (TNBC) Trial in Beijing (TQB2450 Injection and Anlotinib Hydrochioride Capsules)

Unknown status
  • Triple Negative Breast Cancer (TNBC)
  • TQB2450 Injection and Anlotinib Hydrochioride Capsules
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 29, 2019